References
- Menko FH, Maher ER, Schmidt LS, Middelton LA, Aittomäki K, Tomlinson I, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): Renal cancer risk, surveillance and treatment. Fam Cancer. 2014;13(4):637–644. 10.1007/s10689-014-9735-2.
- Patel VM, Handler MZ, Schwartz RA, Lambert WC. Hereditary leiomyomatosis and renal cell cancer syndrome: An update and review. J Am Acad Dermatol. 2017;77(1):149–158. 10.1016/j.jaad.2017.01.023.
- Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374(2):135–145. 10.1056/NEJMoa1505917.
- Lv Y, Song L, Hu M. Fumarate hydratase-deficient renal cell carcinoma: A case report and review of the literature. J Med Case Rep. 2023;17(1):182. 10.1186/s13256-023-03841-0.
- Nikolovski I, Carlo MI, Chen YB, Vargas HA. Imaging features of fumarate hydratase-deficient renal cell carcinomas: A retrospective study. Cancer Imaging. 2021;21(1):24. 10.1186/s40644-021-00392-9.
- Paschall AK, Nikpanah M, Farhadi F, Jones EC, Wakim PG, Dwyer AJ, et al. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. Clin Imaging. 2020;68:14–19. 10.1016/j.clinimag.2020.06.010.
- Wu G, Liu G, Wang J, Pan S, Luo Y, Xu Y, et al. MR spectroscopy for detecting fumarate hydratase deficiency in hereditary leiomyomatosis and renal cell carcinoma syndrome. Radiology. 2022;305(3):631–639. 10.1148/radiol.212984.